Introduction
Laryngopharyngeal reflux disease (LPRD) refers to the retrograde flow of gastric content to the laryngopharynx, where it comes in contact with tissues of the upper aerodigestive tract. It has been estimated that up to 10% of patients presenting to an otolaryngologist's office [1] and more than 50% of patients with hoarseness have disease for which reflux is either the prime etiologic agent or a significant aggravating factor [2] . Despite the apparent ubiquity of this disorder, there remain a number of unanswered questions relating to LPRD. Our report will focus on currently available data regarding the diagnostic significance of LPRD-related symptoms and signs, the role of pH monitoring in the diagnosis and management of LPRD, current, evidenced-based treatment regimens, and the role of surgical options in the LPRD treatment algorithm. This review will be placed within the context of the authors' usual practice and includes a treatment algorithm, which reflects our current practice protocol.
Symptoms
Laryngopharyngeal reflux should be suspected when clinical history and initial findings are suggestive. Of paramount importance is the recognition of LPRD as different from gastroesophageal reflux disease (GERD); failure to do so has been both a source of frustration for treating physicians and confusion for patients. Koufman [1] recognized and described this distinction early. In a combined reported series of 899 patients, he noted that throat clearing was a complaint of 87% of LPRD patients compared with 3% of those with GERD, whereas only 20% of LPRD patients complained of heartburn compared with 83% in the GERD group [1] . Based on a study of pH-monitoring-confirmed LPRD cases, Belafsky et al. [3] developed a self-administered tool, the reflux symptom index (RSI). This instrument is useful in determining the degree to which presenting symptoms may be related to LPRD. It can also be used to monitor symptomatic response to LPRD treatment. The RSI score in untreated LPRD patients was found to be significantly higher than in controls. As the 95% upper confidence limit for controls was 13.6, a RSI score greater than 13 is considered abnormal.
Typical LPRD-related symptoms include throat clearing, hoarseness, excessive mucus production, chronic cough, and globus pharyngeus [1, 4] . Despite these symptoms being quite protean, often a constellation of these symptoms with or without the typical GERD symptoms raises the possibility to the clinician of LPRD. The hoarseness complaint is usually fluctuating in nature and is often present in the morning and then improves throughout the day. This symptom 'finding' is quite unique to LPRD. Some authors have found a strong association between LPRD and subglottic stenosis, obstructive sleep apnea, laryngospasm, bronchiectasis, and chronic rhinitis [5] [6] [7] [8] [9] . Another reflux-related entity that figures prominently in our practice is chronic cough secondary to paradoxical vocal-fold motion disorder (PVFMD). These cases are characteristically referred for otolaryngologic evaluation after extensive pulmonary work-up and often prolonged treatment for presumed adult-onset asthma. Evidence of a fixed extrathoracic obstruction on pulmonary function testing and a high index of clinical suspicion lead the evaluating physician to pursue laryngologic consultation.
Clinical findings
Many of the typical LPRD symptoms are nonspecific and may be caused by other conditions such as smoking, allergies, and neurogenic mechanisms [4] . These symptoms are, nevertheless, attributed to LPRD on the basis of laryngoscopic examination in which the presence of edema and erythema are considered synonymous with LPRD [1, 4, 10] . In a study by Qadeer et al. [11 • ], edema and erythema were the most common (approximately 60%) findings responsible for LPRD diagnosis. This also appears to be the most prevalent method of LPRD diagnosis in many ear, nose and throat practices across the USA, irrespective of teaching or nonteaching status [12] . In a survey of approximately 2000 gastroenterologists and ear, nose and throat physicians, for instance, Ahmed et al. [12] reported that edema and erythema of the larynx were the most common reasons for LPRD diagnosis.
The specificity of these findings for diagnosing LPRD has been questioned, however. In an earlier study, Hicks et al. [13] found that up to 87% of healthy volunteers had at least one sign attributed to LPRD. More recently, Milstein et al. [14] found a similarly high percentage of a healthy population having laryngeal abnormalities. The latter study also found that the choice of endoscopic instruments influenced laryngoscopic findings, with flexible fiber-optic laryngoscopy being more likely to falsely suggest the presence of erythema and edema than rigid laryngoscopy. The subjective nature of the laryngeal examination was further evidenced in a study by Branski et al. [15] . In their study, 120 video segments from rigid fiber-optic laryngeal examinations were prospectively analyzed and scored for GERD-related laryngeal signs by five blinded, board-certified otolaryngologists. They found both poor inter-rater and intra-rater reliability leading them to conclude that 'such variability makes the precise laryngoscopic diagnosis of LPRD highly subjective'. Given poor reliability, specificity and positive predictive value, we do not recommend relying solely on these findings to diagnose LPRD.
In an effort to identify laryngoscopic signs more specific for LPRD, Belafsky et al. [16] developed an eight-item clinical severity scale based on laryngeal abnormalities present in the subglottic, posterior commissure, and vocal-fold areas, as well as the presence of ventricular obliteration, granuloma, or diffuse laryngeal edema. A 'reflux finding score' (RFS) score of greater than 7 was found to suggest GERD-associated laryngitis (Fig. 1) . The RFS relies significantly on laryngeal erythema and edema, however, and has not been validated in an independent population. Careful examination of the degree of edema (or lack thereof) of the supraglottic structures (aryepiglottic folds, arytenoid apex, cuneiform, and corniculate cartilages) has been found in our practice to be a useful site to diagnose and monitor LPRD.
The association of various laryngeal findings listed in the RFS has been looked at in several recently published studies. In a study by Hill et al. [17] , it was reported that pachydermia, as an isolated finding, is unreliable in determining the presence of active LPRD. On the other hand, Hickson et al. [18] found that laryngeal pseudosulcus (more aptly named infraglottic edema) is, indeed, an accurate predictor of LPRD. Similarly, in a prospective study of ear, nose and throat patients with suspected GERD whose symptoms improved with aggressive acid-suppressive therapy (proton-pump inhibitors (PPIs) twice daily (b.i.d.)), abnormalities in the arytenoid medial wall and vocal cords were found both to predict treatment response and to improve with medical therapy for LPRD [11 • ].
Despite such positive results, laryngoscopic findings remain misleading and the lack of a reliable clinical mar-ker has confounded progress in the diagnosis and treatment of LPRD. The symptoms and physical findings of LPRD can be confused with other laryngeal inflammatory conditions as well as nonpathological variations. Furthermore, little is known about the nature and timing of LPRD-related laryngeal changes over time following treatment. Often, successfully treated LPRD patients' laryngeal examinations do not substantially change over time following prolonged PPI treatment. A breakthrough in LPRD diagnosis may evolve from recent immunohistochemical studies of laryngeal biopsy specimens showing concentration of pepsin and depletion of carbonic anhydrase isoenzyme III in documented LPRD cases [19] . Until such advances are verified, validated, and become widely available, however, we advocate initiating an empiric therapeutic/diagnostic trial when GERD-related laryngitis is suspected based on the clinical impression integrating a patient's history, RSI score (>13), and laryngeal examination.
Diagnostic testing
Standards for evaluating laryngopharyngeal reflux continue to evolve as the individual roles of the various applicable diagnostic modalities become better defined. The following discussion presents the author's approach to the problem of diagnosing laryngopharyngeal reflux as well as monitoring both its response to treatment and its sequelae.
Establishing a diagnosis of laryngopharyngeal reflux disease
In addition to following the response of symptoms to behavioral and empirical medical treatment, a diagnosis of LPRD can be confirmed via either pH monitoring or impedance studies. Additional applicable studies include radiography, esophageal manometry, spectrophotometric measurement of bile reflux, and mucosal biopsy, all of which can provide further information useful in targeting therapy. Despite the number of available diagnostic modalities, documentation of the pathogenic role of gastric acid reflux in LPRD remains problematic. pH-recording studies, for instance, have shown pharyngeal acid reflux events in only 60-70% of LPRD patients [20] [21] [22] . Furthermore, as many as 20% of the healthy volunteers manifest pharyngeal acid reflux events [23] , yielding an unacceptable sensitivity and specificity for clinical use of this test. More importantly, these findings add to the difficulty in establishing a cause-and-effect relationship between refluxed gastric acid and LPRD. These issues are compounded by the lack of agreement on normative values and variability in testing methods, especially relating to the positioning of the upper pH probe. In some studies, for example, the proximal probe was placed below the upper esophageal sphincter, whereas in others placement was in the hypopharynx which, although considered closer to the site of injury, is also subject to spurious drops in pH related to intermittent probe drying [24] .
Despite these facts, several recommendations regarding testing and management of LPRD can be made. For pH-monitoring studies, current recommendations suggest placing the hypopharyngeal probe 2 cm above the manometric upper esophageal sphincter (UES) [4] . The distal and proximal esophageal pH probes should be placed 5 and 15 cm above the manometric lower esophageal sphincter (LES), respectively. While largely based on lower esophageal standards applied to GERD, an abrupt decrease in pH to less than 4 in the proximal probe following, or synchronous with, a drop at the lower esophageal sphincter is considered a significant value [25 •• ] . In the hypopharynx, a drop in pH to less than 5 has been postulated by some to be a more reliable indicator of proximal reflux due to pH neutralizing factors such as saliva and airway secretions [26] . A recently published meta-analysis of 16 double pHprobe studies in which techniques met the above criteria showed consistency and accuracy in distinguishing healthy persons from those with LPRD. This study affirmed that, whereas healthy persons experienced some reflux events, the acid exposure time percentage is very reliable in differentiating persons with and without LPRD [25 •• ] .
Monitoring response to empiric treatment
The current recommendation for patients with LPRD symptoms unresponsive to b.i.d. PPI therapy is to perform pH monitoring on therapy in order to ensure adequate acid suppression [4] . Charbel et al. [27] recently reported, however, that 99% of extra esophageal GERD patients on b.i.d. PPIs tested normal on esophageal pH monitoring, casting doubt on the clinical utility and cost-effectiveness of such a recommendation. It must be pointed out, however, that esophageal pH monitoring detects gastroesophageal reflux by its acid 'fingerprint' (i.e. pH < 4), but provides limited information on volume reflux of a 'nonacid' type. Earlier studies have shown that PPI therapy primarily changes the composition of gastroesophageal refluxate from acid to nonacid [28] and that the presence of volume alone in the esophagus can be temporarily associated with symptoms [29] . In fact, data from a multicenter study using combined multichannel intraluminal impedance and pH monitoring indicate that persistent symptoms are associated with acid reflux in only 20% of patients on PPI therapy. In approximately 40% of patients, the residual symptoms are due to nonacid reflux, whereas in the remaining 40% of patients the symptoms are not related to GERD episodes [30] . In a recent report, Sasaki et al. [31 • ] demonstrated marked inflammatory histological changes in rat laryngeal mucosa exposed to bile salts in both acid and alkaline media; it was suggested that biliary and acid reflux may exert a synergic role in damaging esophageal mucosa. These findings might also explain some of the therapeutic failures of acid suppression used as the sole treatment for LPRD. Current stateof-the-art technology using combined impedance and pH provides the means to accurately detect reflux of all types, independent of pH, and to identify its relationship to persistent symptoms [32] .
Screening examinations of the esophagus
We believe that all patients should be submitted to endoscopic examination to detect other underlying gas- troesophageal disease, the development of which could be masked in a purely empiric approach to LPRD treatment ( Fig. 2) . Endoscopic examination should include either transnasal esophagoscopy or esophagogastroduodenoscopy (EGD), both of which are useful in detecting characteristic associated mucosal injury, esophagitis, and Barrett's esophagus [33] . While EGD reveals esophageal lesions in 50% of typical GERD patients, it is abnormal in less than 20% of LPRD laryngitis patients [34] . We nevertheless believe in the importance of a screening examination of the esophagus in all patients in whom the diagnosis of LPRD is confirmed, either by response to empiric therapy or pH monitoring.
Treatment
The treatment of LPRD has evolved over time as new classes of medications have become available. Initial regimes consisting of dietary modification and antacids were essentially ineffective for LPRD. The introduction of histamine-2 receptor antagonists (H2RAs) constituted the first breakthrough, with response rates for LPRD reported at 50% [35, 36] . It was not until the introduction of PPIs in the late 1980s, however, that pharmacologic suppression of acid production reached levels adequate for the effective and reliable treatment of LPRD. By directly targeting H + -K + ATPase, the key enzyme in the final acid production pathway in the parietal cell, this class of medications allows for the marked suppression of acid production. This not only prevents exposure of the upper aerodigestive tract to acid, but, perhaps more importantly, reduces the damaging enzymic activity of pepsin which requires an acidic environment for activation [37] .
As a result of continued controversies relating to the diagnostic criteria for LPRD, empiric therapy is currently a widely used treatment modality. Such a regimen should include both diet and behavior modification, as well as a concurrent trial of acid-suppressing medication. Behavioral changes we stress include weight loss, smoking cessation, and alcohol avoidance. Ideal dietary changes would restrict chocolate, fats, citrus fruits, carbonated beverages, spicy tomato-based products, red wines, caffeine, and late-night meals. Interestingly, these GERD-behavior modifications have been shown to be an independently significant variable in determining response to pharmacologic therapy [38] . Current evidence indicates and our own anecdotal experience supports the fact that pharmacologic intervention should include, at a minimum, a 3 month trial of twice daily (b.i.d.) PPI. It is important to stress the optimal schedule for taking PPI medications since ingestion of the PPI 30-60 min before meals will provide the highest medication concentration at the time of stimulation of the proton pumps by food intake. As an adjunct, we have found that the as-needed addition of antacids can serve to mitigate the effects of occasional noncompliance with diet and behavior recommendations.
Current evidence tells us that clinical response to such an empiric PPI-based therapeutic trial remains frustratingly variable, however [39] . This is in large part due to the failure of clinical trials to uniformly define inclusion criteria and stratify study groups based on LPRD severity. Duration and dosing of medication regimens are also often inadequate and uncontrolled. Nevertheless, some patterns have emerged from recently published studies. Studies of once-a-day (q.d.) dosing, for instance, have uniformly demonstrated significant failure rates [40, 41] . The average morning dose of a PPI has been shown to last an average of only 13.8 h [42] whereas an evening dose lasts an even shorter 7.5 h [43] . Most current treatment trials therefore suggest a need for b.i.d. PPI regimens. Park et al. The optimal treatment regimen remains complicated, however, by studies suggesting that nocturnal acid breakthrough (NAB) may underlie incomplete treatment response [43, 45, 46] . At night, there is little esophageal motor activity but high LES pressure. Hence, if an episode of GERD occurs, it is generally prolonged. Nocturnal relaxation of the UES as well as a decrease in the nighttime cough reflex further predispose to laryngeal sequelae of GERD. Several authors have examined the role of H2RAs in controlling NAB. In one such study, Peghini et al. [43] report that giving H2RAs at bedtime (h.s.), in addition to an existing b.i.d. PPI regimen, controls NAB better than b.i.d. with h.s. PPI therapy. Conversely, in a prospective study, Fackler et al. [47] , found that the addition of h.s. H2RA to b.i.d. PPI therapy reduced NAB only at the introduction of therapy. As a result of H2RA tolerance, they found no difference in acid suppression between b.i.d. PPI and b.i.d. PPI with H2RA after 1 week of combination therapy [47] . These findings parallel those of Ours et al. [48] who examined the clinical significance of NAB and its effect on esophageal acid exposure and symptoms. These authors found that b.i.d. doses of PPIs resulted in similar 24 h gastricacid suppression to that achieved with an H2RA added to b.i.d. PPIs [48] . Currently, therefore, it is unclear whether the addition of an H2RA to b.i.d. PPIs offers any additional benefit in the long-term control of LPRD. In our own practice, insurance company restrictions typically require documented failure on q.d. PPI prior to approval for b.i.d. regimens. As a result, our de-novo treatment regimen typically consists of q.d. PPI in addition to high-dose H2RA (i.e. ranitidine, 300 mg) before bedtime for 3 months. We find that about two-thirds of patients will report significant improvement on this regimen, unless gross noncompliance with behavior modification exists. If symptoms persist at the 3 month follow-up visit, we escalate to b.i.d. PPIs with h.s. H2RAs, again, for a 3-month period.
An important limitation of acid-suppressing regimens is duodenogastroesophageal reflux. In a recent study, duodenogastroesophageal reflux did not respond to medical treatment in any of the patients, but was effectively controlled by antireflux surgery [49] . Indeed, a wide spectrum of pathophysiologic mechanisms in GERD, such as impaired esophageal and antroduodenal motility, delayed gastric emptying, reflux of duodenal juice, and alteration of gut neuropeptides, are not controlled by acid suppression alone. For these reasons, patients who fail medical therapy may respond to surgical antireflux procedures [50] . The proven success of laparoscopic antireflux surgery, has, in fact, lowered the threshold to refer patients for surgical therapy. Patients with demonstrable high-volume liquid reflux and lower sphincter incompetence are often considered candidates for surgical intervention. In one study, Oelschlager et al. [51] reported a significant decrease in pharyngeal reflux (7.9 to 1.6 episodes per 24 h) and esophageal acid exposure (7.5% to 2.1%) following laparoscopic Nissen fundoplication surgery. The majority of other published reports contradict this finding, however [52] [53] [54] [55] . In general, these studies have found that there is a poor surgical outcome in patients unresponsive to aggressive medical treatment before fundoplication. In one report, So et al. [53] studied 150 consecutive patients after fundoplication, and found that only 56% of patients had obtained relief of atypical symptoms, whereas the typical symptom of heartburn resolved in 93%. In addition, the only preoperative predictors of relief of atypical symptoms were earlier clinical response to pharmacologic acid suppression and abnormal hypopharyngeal pH results.
Conclusion
Patients in whom we suspect LPRD based on clinical evaluation are treated with diet and lifestyle modification in addition to an empiric 3 month trial of q.d. PPI therapy with an H2RA before bedtime. Patient compliance with the use of a PPI 30-60 min before eating is essential for successful treatment of LPRD. In our experience, approximately two-thirds of patients will report improvement on this regimen. Patients who report full resolution are maintained on this regimen and are referred for screening esophagoscopy. Treatment is continued for a minimum of 6 months. When the patient has remained asymptomatic (RSI < 10) and has had two consecutive normal laryngoscopic examinations (RFS < 10), we provide the patient with the option for tapering their medications. Tapering PPIs appears to be important given that abruptly discontinuing these medications often results in a rebound of symptoms. We encourage continued adherence to successful behavior modification protocols while the PPI dose is replaced by a second H2RA dose. If the patient remains asymptomatic, he or she is allowed to discontinue standing doses of medication and use H2RAs or antacids on an as-needed basis. Our experience has shown that less than 10% of LPRD patients are able to remain symptom-free without PPI treatment. Recurrence of symptoms, either during tapering, or after a symptom-free period leads to a resumption of PPI therapy. Professional voice users, especially singers, are encouraged to remain on their effective treatment regimen for the duration of their voice-dependent careers.
Patients with partial response to the initial treatment regimen are escalated to a b.i.d. PPI with h.s. H2RA schedule. Comorbid conditions accounting for incomplete response are ruled out. Gastropareisis, for instance, should be treated with a promotility agent such as metoclopramide in diabetic patients. Patients in whom paradoxical vocal-fold motion disorder is a contributing factor need concomitant respiratory retraining therapy to adequately treat symptoms of chronic cough. In the face of complete lack of response, an LPRD label should not be rigidly maintained, especially given the unreliable nature of establishing this diagnosis. Such cases may warrant consideration of rheumatologic or allergic etiologies of laryngeal inflammation. Also, the possibility of voice or tobacco abuse, or exposure to other toxic inhalants, may need to be considered. If reflux remains likely based on the patient's history and examination, pH-monitoring studies are obtained on medications to evaluate drug efficiency. In the face of significant hypopharyngeal reflux episodes, we either change the brand of PPI or increase the dose to a three times-a-day schedule.
Patients who respond to treatment, but are unable to tolerate PPIs due to side-effects, those who demonstrate continued hypopharyngeal reflux episodes on maximal therapy, and those in whom nonacid reflux is demonstrated by impedance studies are referred for fundoplication.
